<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transforming growth factor-beta (TGF-beta) controls a wide spectrum of cellular processes </plain></SENT>
<SENT sid="1" pm="."><plain>Deregulation of TGF-beta signaling contributes to the pathogenesis of many diseases including <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>TGF-beta signaling is generally mediated through intracellular signal transducers and transcription factors called Smads </plain></SENT>
<SENT sid="3" pm="."><plain>Herein, we have identified the oncoprotein BCL6 as a transcriptional corepressor of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor Smad4 </plain></SENT>
<SENT sid="4" pm="."><plain>BCL6 physically interacts with Smad3 and Smad4, disrupts the Smad-p300 interaction, and represses the transcriptional activity of Smad4 </plain></SENT>
<SENT sid="5" pm="."><plain>In accordance, B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells with a high expression level of BCL6 were found to be refractory to TGF-beta antiproliferative response, whereas knockdown of BCL6 expression in B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells partially restores the TGF-beta responses </plain></SENT>
<SENT sid="6" pm="."><plain>This study provides strong evidence that overexpression of BCL6 contributes to TGF-beta resistance in B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>